Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2025 Jun 19;18:17562864251342855. doi: 10.1177/17562864251342855

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2025

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 2. — The central effects of CladT. (a) Reduction of OCB in the CSF of patients with MS treated with CladT (clad). (b) Reduction of NfL levels in CSF samples collected pre- and post-treatment. (c) Reduction of protein levels of CXCL13 in the CSF and the transcripts of the CXCL13 receptor (CXCR5) in peripheral blood. (d) The role of CladT in preventing further brain atrophy is associated with a reduction in cumulative SELs and CUA lesions in patients with MS with grey matter damage.

CladT, cladribine tablets; CSF, cerebrospinal fluid; CUA, combined unique active; MS, multiple sclerosis; NfL, neurofilament light chain; OCB, oligoclonal bands; SEL, slowly expanding lesion.